Summit Therapeutics Today Presents Its Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference

Rhea-AI Summary

Summit Therapeutics (NASDAQ: SMMT) will present its future development plans at the 40th Annual J.P. Morgan Healthcare Conference today at 3:45 PM EST. CEO Robert W. Duggan and COO Dr. Maky Zanganeh will discuss the company’s research and clinical development objectives. The presentation will be available live on Summit's website, with an archived version accessible later. Summit aims to lead in patient-friendly treatments for infectious diseases, focusing on its lead candidate ridinilazole, currently in Phase III trials, and SMT-738, targeting multidrug-resistant infections.

Positive

• Summit’s lead product candidate, ridinilazole, is in a global Phase III trial program.
• SMT-738 is in the IND-enabling phase for treating multidrug-resistant infections.
• The company is supported by significant funding from BARDA, CARB-X, and Wellcome Trust.

Negative

• None.

Cambridge, Massachusetts, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) reminds interested stakeholders that it will today present the Company’s vision and its intended future development pathways at the 40^th Annual J.P. Morgan Healthcare Conference at approximately 3:45 PM EST.  Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Operating Officer and a member of Summit’s Board of Directors, will provide details regarding Summit’s current plans with respect to its future research and clinical development goals.

A live version of the presentation will be accessible on the home page of our website: https://www.summittxinc.com. An archived edition of the session will be available later in the day.

About Summit Therapeutics

The overriding objective of Summit Therapeutics is to create value for patients, hospital caregivers, community-based healthcare providers, healthcare payers around the world, in addition to our highly valued stakeholders and shareholders. We intend to create value by developing drugs with high therapeutic efficacy – intending to cure the cause and related effects of the patient's condition in need with minimal patient trauma over time. Summit Therapeutics, supported by BARDA, CARB-X and Wellcome Trust funding, intends to be the leader in patient-friendly and paradigm-shifting treatments for significant unmet medical needs, including infectious diseases. Our new era, novel mechanism pipeline product candidates are designed with the goal to become the patient-friendly, new-era standard of care, are designed to work in harmony with the human microbiome. Currently, Summit’s lead product candidate, ridinilazole, is a novel, first-in-class drug engaged in a global Phase III trial program. Commercialization of ridinilazole is subject to regulatory approvals. SMT-738, the second candidate within Summit’s portfolio, is currently in the IND-enabling phase for the treatment of multidrug resistant infections, specifically those caused by carbapenem-resistant Enterobacteriaceae (CRE).

For more information, please visit https://www.summittxinc.com and follow us on Twitter @summitplc.

Contact Summit Investor Relations:

Dave Gancarz
Head of Stakeholder Relations & Corporate Strategy
david.gancarz@summitplc.com

General Inquiries: 
investors@summitplc.com

Summit Forward-looking Statements

Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the impact of the COVID-19 pandemic on the Company’s operations and clinical trials and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including:  the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, global public health crises, including the coronavirus COVID-19 outbreak, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that the Company makes with the Securities and Exchange Commission.  Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ridinilazole.  Accordingly, readers should not place undue reliance on forward-looking statements or information.  In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date.  The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

FAQ

What is the purpose of Summit Therapeutics' presentation at the J.P. Morgan Healthcare Conference?

Summit Therapeutics aims to outline its vision and future development pathways for its drug candidates during the conference.

When is Summit Therapeutics presenting at the J.P. Morgan Healthcare Conference?

Summit Therapeutics will present at approximately 3:45 PM EST on January 10, 2022.

What are the main product candidates of Summit Therapeutics?

Summit Therapeutics' main product candidates include ridinilazole, currently in Phase III trials, and SMT-738, which is being developed for multidrug-resistant infections.

Where can I watch the Summit Therapeutics presentation?

The presentation will be live-streamed on Summit's website and an archived version will be available later.